AIMD News & Events

Ainos highlighted the continued expansion of its Smell AI deployments, powered by AI Nose, across semiconductor, robotics, and healthcare infrastructure, highlighted by recent third-party research published by VASRO. The company said, "The report underscores Smell AI's progression from isolated sensing applications to scalable multi-domain AI perception platform and identifies 2026 as a key scale-up year as Ainos moves toward deployment and repeatable revenue generation. As part of this expansion, Ainos is initiating deployment of Smell AI within hospital infrastructure through collaboration with MacKay Memorial Hospital and Topco Scientific Co., Ltd. Initial applications focus on environmental monitoring and safety across power and electromechanical systems, HVAC infrastructure, chemical handling environments, and clinical laboratory settings, including MRI facilities. According to the report, these environments position Smell AI as an early perception layer for otherwise invisible environmental signals, including chemical exposure and airborne germs, supporting improved safety and operational resilience in hospital settings. The hospital deployment positions Smell AI to extend beyond its established semiconductor and industrial use cases into another high-standard operating environment, reinforcing its ability to scale across real-world infrastructure. The report also highlights Smell AI's evolution toward broader platform adoption through AI Nose, which converts invisible scent signals into structured, machine-readable Smell ID data that can compound across deployments."

Ainos announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology across high-risk hospital environments. The collaboration aims to expand Ainos' Smell AI platform from industrial and environmental safety into healthcare infrastructure. The initial deployment, beginning in April 2026, focuses on environmental monitoring and safety across four critical hospital areas.

"In 2025 we maintained a disciplined financial approach while supporting SmellTech platform's scale. Total revenue increased approximately 499% year over year, mainly reflecting progress in our AI Nose commercialization. Gross margin improved significantly to approximately 82.9% in 2025, compared to a gross loss in 2024. Total operating expenses, excluding share-based compensation, depreciation and amortization, decreased 9% year-over-year, reflecting operational discipline as we prepare for deployment-driven growth, while reported operating expense increased about 2%," Christopher Lee, CFO, commented. "Subsequent to year-end, we strengthened our financial position through a New Taiwan Dollar 90 million financing, providing additional liquidity to support ongoing operations and deployment execution. This capital enhances our flexibility as we scale AI Nose commercialization while maintaining a disciplined approach to capital allocation," Lee added.

"2025 marked our transition in expanding AI Nose's commercial focus from healthcare into industrial markets. Our focus in 2025 was building the platform and partnerships required for scale," said Eddy Tsai, Chairman and CEO of Ainos. "As we enter 2026, that groundwork is translating into operational momentum, with early AI Nose deployments underway, particularly in semiconductor environments. As deployments expand, AI Nose generates Smell ID data that continuously trains our SLM, reinforcing our long-term data advantage."